Appropriateness of Empirical Fluoroquinolones Therapy in Patients Infected with Escherichia coli, Klebsiella pneumoniae, or Pseudomonas aeruginosa: The Importance of the CLSI Breakpoints Revision

References

• World Health Organization. Antimicrobial Resistance: Global Report on Surveillance 2014. Geneva, Switzerland: World Health Organization; 2014.
   Google Scholar
• ZengS, XuZ, WangX, et al. Time series analysis of antibacterial usage and bacterial resistance in China: observations from a tertiary hospital from 2014 to 2018. Infect Drug Resist. 2019;12:2683–2691. doi:10.2147/IDR.S22018331695444
   PubMed Web of Science ®Google Scholar
• RoopeLSJ, SmithRD, PouwelsKB, et al. The challenge of antimicrobial resistance: what economics can contribute. Science. 2019;364(6435):eaau4679. doi:10.1126/science.aau467930948524
   PubMed Web of Science ®Google Scholar
• BolonMK. The newer fluoroquinolones. Infect Dis Clin North Am. 2009;23(4):1027–x. doi:10.1016/j.idc.2009.06.00319909896
   PubMed Web of Science ®Google Scholar
• EzelarabHAA, AbbasSH, HassanHA, Abuo-RahmaGEA. Recent updates of fluoroquinolones as antibacterial agents. Arch Pharm (Weinheim). 2018;351(9):e1800141. doi:10.1002/ardp.20180014130048015
   PubMed Web of Science ®Google Scholar
• LinderJA, HuangES, SteinmanMA, GonzalesR, StaffordRS. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med. 2005;118(3):259–268. doi:10.1016/j.amjmed.2004.09.01515745724
   PubMed Web of Science ®Google Scholar
• BaggsJ, FridkinSK, PollackLA, SrinivasanA, JerniganJA. Estimating national trends in inpatient antibiotic use among US hospitals from 2006 to 2012. JAMA Intern Med. 2016;176(11):1639–1648. doi:10.1001/jamainternmed.2016.565127653796
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention, US Department of Health and Human Services [Website on the Internet]. Antibiotic resistance threats in the United States. US; 2013. Available from: http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf. Accessed 820, 2021.
   Google Scholar
• YangP, ChenY, JiangS, ShenP, LuX, XiaoY. Association between the rate of fluoroquinolones-resistant gram-negative bacteria and antibiotic consumption from China based on 145 tertiary hospitals data in 2014. BMC Infect Dis. 2020;20(1):269. doi:10.1186/s12879-020-04981-032264851
   PubMed Web of Science ®Google Scholar
• MutnickAH, RhombergPR, SaderHS, JonesRN. Antimicrobial usage and resistance trend relationships from the MYSTIC programme in North America (1999–2001). J Antimicrob Chemother. 2004;53(2):290–296. doi:10.1093/jac/dkh03914711839
   PubMed Web of Science ®Google Scholar
• KimB, KimY, HwangH, et al. Trends and correlation between antibiotic usage and resistance pattern among hospitalized patients at university hospitals in Korea, 2004 to 2012: a Nationwide Multicenter Study. Medicine (Baltimore). 2018;97(51):e13719. doi:10.1097/MD.000000000001371930572507
   PubMed Web of Science ®Google Scholar
• WeistK, HögbergLD. ECDC publishes 2015 surveillance data on antimicrobial resistance and antimicrobial consumption in Europe. Euro Surveill. 2016;21(46):30401. doi:10.2807/1560-7917.ES.2016.21.46.30399
   Google Scholar
• U.S. Department of Health and Human Services. Antibiotic Resistance Threats in the United States, 2013. Centers for Disease Control and Prevention. 2013.
   Google Scholar
• RhombergPR, JonesRN. Summary trends for the meropenem yearly susceptibility test information collection program: a 10-year experience in the United States (1999–2008). Diagn Microbiol Infect Dis. 2009;65(4):414–426. doi:10.1016/j.diagmicrobio.2009.08.02019833471
   PubMed Web of Science ®Google Scholar
• ReddyP. Empiric antibiotic therapy of nosocomial bacterial infections. Am J Ther. 2016;23(4):e982–e994. doi:10.1097/MJT.000000000000004224413366
   PubMed Web of Science ®Google Scholar
• MuscedereJG, ShorrAF, JiangX, DayA, HeylandDK; Canadian Critical Care Trials Group. The adequacy of timely empiric antibiotic therapy for ventilator-associated pneumonia: an important determinant of outcome. J Crit Care. 2012;27(3):322.e7–322.e14. doi:10.1016/j.jcrc.2011.09.004
   Web of Science ®Google Scholar
• Membrilla-FernándezE, Sancho-InsenserJJ, Girvent-MontllorM, Álvarez-lermaF, Sitges-SerraA; Secondary Peritonitis Spanish Study Group. Effect of initial empiric antibiotic therapy combined with control of the infection focus on the prognosis of patients with secondary peritonitis. Surg Infect (Larchmt). 2014;15(6):806–814. doi:10.1089/sur.2013.24025397738
   PubMed Web of Science ®Google Scholar
• FitzpatrickJM, BiswasJS, EdgeworthJD, et al. Gram-negative bacteraemia; a multi-centre prospective evaluation of empiric antibiotic therapy and outcome in English acute hospitals. Clin Microbiol Infect. 2016;22(3):244–251. doi:10.1016/j.cmi.2015.10.03426577143
   PubMed Web of Science ®Google Scholar
• AypakC, AltunsoyA, DüzgünN. Empiric antibiotic therapy in acute uncomplicated urinary tract infections and fluoroquinolone resistance: a Prospective Observational Study. Ann Clin Microbiol Antimicrob. 2009;8:27. doi:10.1186/1476-0711-8-2719852849
   PubMed Web of Science ®Google Scholar
• Castro-SánchezE, Bennasar-VenyM, SmithM, et al. European commission guidelines for the prudent use of antimicrobials in human health: a missed opportunity to embrace nursing participation in stewardship. Clin Microbiol Infect. 2018;24(8):914–915. doi:10.1016/j.cmi.2018.02.03029505878
   PubMed Web of Science ®Google Scholar
• World Health Organization. Laboratory leadership competency framework; 2019. Available from: https://apps.who.int/iris/handle/10665/311445. Accessed 820, 2021.
   Google Scholar
• CuiY, LiuJ, ZhangX. Effects of laboratory capabilities on combating antimicrobial resistance, 2013–2016: a static model panel data analysis. J Glob Antimicrob Resist. 2019;19:116–121. doi:10.1016/j.jgar.2019.03.00730904685
   PubMed Web of Science ®Google Scholar
• VanTT, MinejimaE, ChiuCA, Butler-WuSM. Don’t get wound up: revised fluoroquinolone breakpoints for Enterobacteriaceae and Pseudomonas aeruginosa. J Clin Microbiol. 2019;57(7):e02072–18. doi:10.1128/JCM.02072-1831043468
   PubMed Web of Science ®Google Scholar
• Morency-PotvinP, SchwartzDN, WeinsteinRA. Antimicrobial stewardship: how the microbiology laboratory can right the ship. Clin Microbiol Rev. 2016;30(1):381–407. doi:10.1128/CMR.00066-1627974411
   PubMed Web of Science ®Google Scholar
• HeilEL, JohnsonJK. Impact of CLSI breakpoint changes on microbiology laboratories and antimicrobial stewardship programs. J Clin Microbiol. 2016;54(4):840–844. doi:10.1128/JCM.02424-1526791363
   PubMedGoogle Scholar
• GinocchioCC. Role of NCCLS in antimicrobial susceptibility testing and monitoring. Am J Health Syst Pharm. 2002;59(8 Suppl 3):S7–S11. doi:10.1093/ajhp/59.suppl_3.S7
   Web of Science ®Google Scholar
• CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Ninth Informational Supplement. CLSI document M100-S29. Wayne: Clinical and Laboratory Standards Institute; 2019.
   Google Scholar
• CLSI. Performance Standards for Antimicrobial Susceptibility Testing; 28th Informational Supplement. CLSI document M100-S28. Wayne: Clinical and Laboratory Standards Institute; 2018.
   Google Scholar
• CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 27th informational supplement M100-S27. Wayne: Clinical and Laboratory Standards Institute. 2017.
   Google Scholar
• TsengYT, ChuangYC, ShuCC, HungCC, HsuCF, WangJY. Empirical use of fluoroquinolones improves the survival of critically ill patients with tuberculosis mimicking severe pneumonia. Crit Care. 2012;16(5):R207. doi:10.1186/cc1183923098258
   PubMed Web of Science ®Google Scholar
• ChenCH, WuB, TongHC. Analysis on drug resistance of pathogens and empiric medication in urinary tract infections. Mod Med J. 2015;43(2):173–176. In Chinese.
   Google Scholar
• WarrenJW, AbrutynE, HebelJR, JohnsonJR, SchaefferAJ, StammWE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis. 1999;29(4):745–758. doi:10.1086/52042710589881
   PubMed Web of Science ®Google Scholar
• GrossmanC, KellerN, BornsteinG, Ben-ZviI, Koren-MoragN, RahavG. Factors associated with suitability of empiric antibiotic therapy in hospitalized patients with bloodstream infections. J Chemother. 2017;29(3):159–163. doi:10.1080/1120009X.2016.118277027352218
   PubMed Web of Science ®Google Scholar
• HsuDI, OkamotoMP, MurthyR, Wong-BeringerA. Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes. J Antimicrob Chemother. 2005;55(4):535–541. doi:10.1093/jac/dki02615728150
   PubMed Web of Science ®Google Scholar
• LiuPY, ShiZY, TungKC, et al. Antimicrobial resistance to cefotaxime and ertapenem in Enterobacteriaceae: the effects of altering clinical breakpoints. J Infect Dev Ctries. 2014;8(3):289–296. doi:10.3855/jidc.333524619258
   PubMed Web of Science ®Google Scholar
• ChuYW, TseH, TsangD. Adoption of the new CLSI fluoroquinolone breakpoints for Enterobacteriaceae. J Clin Microbiol. 2019;57(11):e01176–19. doi:10.1128/JCM.01176-1931645411
   PubMed Web of Science ®Google Scholar
• BolonMK, WrightSB, GoldHS, CarmeliY. The magnitude of the association between fluoroquinolone use and quinolone-resistant Escherichia coli and Klebsiella pneumoniae may be lower than previously reported. Antimicrob Agents Chemother. 2004;48(6):1934–1940. doi:10.1128/AAC.48.6.1934-1940.200415155181
   PubMed Web of Science ®Google Scholar
• DurhamLK, GeM, CucciaAJ, QuinnJP. Modeling antibiotic resistance to project future rates: quinolone resistance in Escherichia coli. Eur J Clin Microbiol Infect Dis. 2010;29(3):353–356. doi:10.1007/s10096-009-0862-x20119677
   PubMed Web of Science ®Google Scholar
• BischoffS, WalterT, GerigkM, EbertM, VogelmannR. Empiric antibiotic therapy in urinary tract infection in patients with risk factors for antibiotic resistance in a German emergency department. BMC Infect Dis. 2018;18(1):56. doi:10.1186/s12879-018-2960-929373965
   PubMed Web of Science ®Google Scholar
• ArslanH, AzapOK, ErgönülO, TimurkaynakF; Urinary Tract Infection Study Group. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J Antimicrob Chemother. 2005;56(5):914–918. doi:10.1093/jac/dki34416174685
   PubMed Web of Science ®Google Scholar
• AzapOK, ArslanH, SerefhanoğluK, et al. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin Microbiol Infect. 2010;16(2):147–151. doi:10.1111/j.1469-0691.2009.02941.x19689464
   PubMed Web of Science ®Google Scholar
• Al-ZahraniJ, Al DossariK, GabrAH, AhmedAF, Al ShahraniSA, Al-GhamdiS. Antimicrobial resistance patterns of Uropathogens isolated from adult women with acute uncomplicated cystitis. BMC Microbiol. 2019;19(1):237. doi:10.1186/s12866-019-1612-631666014
   PubMed Web of Science ®Google Scholar
• ZhangYY, WangF, WangZM, et al. The indications and rational use of quinolones in the treatment of infectious diseases: a consensus. Chin J Infect Chemother. 2009;9(02):81–88. ( In Chinese.)
   Google Scholar
• KhaliqY, ZhanelGG. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis. 2003;36(11):1404–1410. doi:10.1086/37507812766835
   PubMed Web of Science ®Google Scholar
• Zhong NS, Wan XR, Ma XJ, et al.Guidelines for the clinical application of antibacterial drugs. National health commission of the People’s Republic of China, national administration of traditional Chinese medicine, medical department of general logistics department. 2015. ( In Chinese).
   Google Scholar
• DiamantisS, RiouxC, BonnalC, et al. Suitability of initial antibiotic therapy for the treatment of bloodstream infections and the potential role of antibiotic management teams in improving it. Eur J Clin Microbiol Infect Dis. 2012;31(7):1667–1671. doi:10.1007/s10096-011-1491-822134774
   PubMed Web of Science ®Google Scholar
• LeeCC, LeeCH, ChuangMC, HongMY, HsuHC, KoWC. Impact of inappropriate empirical antibiotic therapy on outcome of bacteremic adults visiting the ED. Am J Emerg Med. 2012;30(8):1447–1456. doi:10.1016/j.ajem.2011.11.01022205015
   PubMed Web of Science ®Google Scholar
• MosdellDM, MorrisDM, VolturaA, et al. Antibiotic treatment for surgical peritonitis. Ann Surg. 1991;214(5):543–549. doi:10.1097/00000658-199111000-000011953104
   PubMed Web of Science ®Google Scholar
• GuoN, XueW, TangD, DingJ, ZhaoB. Risk factors and outcomes of hospitalized patients with blood infections caused by multidrug-resistant Acinetobacter baumannii complex in a hospital of Northern China. Am J Infect Control. 2016;44(4):e37–e39. doi:10.1016/j.ajic.2015.11.01926804303
   PubMed Web of Science ®Google Scholar